An interventional study of Gastric tube (Nutricia Flocare® Pur Tube Enlock) and Jejunal tube (Nutricia Flocare® Bengmark®) in Malnutrition and Liver Diseases, Alcoholic, sponsored by University of Aarhus. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-20.
Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment
The study is an unblinded randomized trial, designed to examine whether gastric- or jejunal feeding tubes are the most effect full to feed patients with alcoholic liver diseases and non-sufficient oral intake.
The primary outcome will be differences in nutrition intake between the groups. Secondary outcomes will be: the amount of unplanned tube discontinuations; handgrip and patients' quality of life, nausea \& vomiting.
The study will include 40 patients at Aarhus University Hospital, Denmark.
2,081 studies on the registry are indexed under Liver Diseases; 389 are open to participants now.
This study's enrollment of 40 is below the median of 50 across 1,322 interventional studies indexed under Liver Diseases.
Browse Liver Diseases studies →University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
A gastric tube is used
Device: Gastric tube (Nutricia Flocare® Pur Tube Enlock)
A jejunal tube is used
Device: Jejunal tube (Nutricia Flocare® Bengmark®)
Nutricia Flocare® Pur Tube Enlock, Ch. 12
Nutricia Flocare® Bengmark®, Ch. 10
Differences in nutrition intake
Nutrition intake, protein intake, oral intake versus tube intake
Time frame: Day 3 & 7 and every 7th. day until discharge from the hospital, up to 3 months
Differences in patients reported outcomes
Questionnaires
Time frame: Day 3 & 7 and every 7th. day until discharge from the hospital, up to 3 months
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Aarhus